| |
|
|
|
|
|
|
|||
|
Blood, 1 August 2004, Vol. 104, No. 3, pp. 815-821. Prepublished online as a Blood First Edition Paper on April 15, 2004; DOI 10.1182/blood-2004-01-0292.
Submitted January 28, 2004
the Laboratory of Cellular Immunology, Ochsner Clinic Foundation, New Orleans, LA, USA * Corresponding author; email: ychoi{at}ochsner.org.
The lymphoid follicle is a specialized microenvironment for the differentiation of Ag-activated B cells; the major stromal cell components in lymphoid follicle are the follicular dendritic cells (FDC). At the same time, the majority of B cell lymphomas originate from the germinal center, and the generation and blast transformation of B cell lymphoma occurs in close association with FDC in the early stage of tumorigenesis. To study the functional roles of FDC in lymphomagenesis, we established an inducible tumor model. The human B cell lymphoma cell line, L3055, formed solid tumors only when inoculated with an FDC line, HK. In addition, two FDC-signaling molecules (FDC-SMs), a novel protein 8D6 and 4G10/CD44, are required for tumor formation in vivo, because mAbs specific to these two proteins inhibited lymphomagenesis completely when they were inoculated with L3055 and HK cells. However, these two FDC-SMs have distinct functional roles in tumor formation. FDC-SM-8D6 enhances L3055 cell proliferation while FDC-SM-4G10/CD44 inhibits its apoptosis. Identification of functional role of these critical FDC-SMs may lead to the discovery of therapeutic drugs that suppress the survival and growth of lymphoma cells.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2004 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||